MAPT and Alzheimer disease: Our hypothesis was that MCI participants with an AD CSF profile (reduced Aβ and elevated tau) would show higher macular VD measures than those participants with a normal CSF profile, in line with the results of a recent publication from our group (Marquié et al., 2022).